GenMark Diagnostics, Inc. (GNMK) - NASDAQ
  • Wed, Feb. 24, 12:48 PM
    | Wed, Feb. 24, 12:48 PM | 6 Comments
  • Wed, Jan. 13, 12:43 PM
    | Wed, Jan. 13, 12:43 PM | 24 Comments
  • Oct. 28, 2015, 10:21 AM
    • Thinly traded micro cap GenMark Diagnostics (GNMK -26.4%) is off on 30% higher volume, albeit on turnover of only 320K shares, in response to its disclosure in yesterday's earnings call that the European launch of its ePlex System will be delayed until Q1.
    • The culprit is an unacceptably high level of variability in the reliability of the tests due to a particular injection molded part in the ePlex cartridge. The ability to manufacture two components which play key roles in the maintenance of reliable cartridge fluidics during operation has apparently been a challenge.
    | Oct. 28, 2015, 10:21 AM
  • Apr. 17, 2015, 12:45 PM
    | Apr. 17, 2015, 12:45 PM
  • Aug. 12, 2013, 6:05 PM
    • GenMark Diagnostics (GNMK) announces a $60M public offering.
    • All of the shares in the proposed offering are to be sold by GNMK.
    • JPMorgan is acting as sole book-runner. Shares -5% AH.
    | Aug. 12, 2013, 6:05 PM
  • Aug. 12, 2013, 4:12 PM
    • GenMark Diagnostics (GNMK) announces a public offering of $60M in common stock. J.P. Morgan is the sole bookrunner. (PR)
    • Shares -2.7% AH.
    | Aug. 12, 2013, 4:12 PM
  • Aug. 7, 2013, 5:51 PM
    • GenMark Diagnostics (GNMK): Q2 EPS of -$0.25 in-line.
    • Revenue of $5.22M beats by $0.17M. Shares +5.4% AH. (PR)
    | Aug. 7, 2013, 5:51 PM
  • Jun. 18, 2013, 3:21 PM
    J.P. Morgan isn't giving up on GenMark Diagnostics (GNMK -12.2%) despite the shares' ~35% decline since June 10. Analyst Tycho Peterson acknowledges the company's tepid guidance, but maintains an Overweight rating on the stock. PT lowered to $15 from $17.
    | Jun. 18, 2013, 3:21 PM
  • Jun. 17, 2013, 5:30 PM
    After-hours top gainers, as of 5:15 p.m.: NSU +4%. URI +4%. TMHC +4%. COCO +3%. HA +3%.
    After-hours top losers: GNMK -6%. LOPE -6%. SFL -6%. STAA -4%. BLDR -3%.
    | Jun. 17, 2013, 5:30 PM
  • Jun. 17, 2013, 4:53 PM

    GenMark Diagnostics (GNMK) falls 6.5% AH on top of 8.35% during the regular session. The company says it now sees FY13 revenue of ~$30M versus the $35M it originally estimated. GNMK cites "additional uncertainties relating to the future revenue contribution from its largest customer" (previous).

    | Jun. 17, 2013, 4:53 PM
  • Jun. 11, 2013, 12:45 PM
    Midday top 10 gainers: SGOC +56%. BEAT +53%. UQM +30%. PGNX +26%. DOLE +21%. NOA +21%. QCOR +20%. VNDA +19%. ALTI +13%. CMGE +13%.
    Midday top 10 Losers: GNMK -23%. LULU -17%. SMA -16%. ALVR -15%. LDK -10%. PRIS -10%. RSOL -10%. IMUC -9%. ECTE -9%. COCO -9%.
    | Jun. 11, 2013, 12:45 PM | 1 Comment
  • Jun. 11, 2013, 12:41 PM

    Shares of GenMark Diagnostics (GNMK -25%) get slammed after one of its customers, Natural Molecular Testing, launches their laboratory developed comprehensive Personalized Medicine Panel using Luminex's (LMNX +6%) xMAP technology. Terms of the multi-year collaboration and license agreement were not disclosed.

    | Jun. 11, 2013, 12:41 PM
  • May 8, 2013, 4:47 PM
    GenMark Diagnostics (GNMK): Q1 EPS of -$0.13 beats by $0.04. Revenue of $11.1M beats by $1.57M. Shares -1.3% AH. (PR)
    | May 8, 2013, 4:47 PM
  • Jan. 4, 2013, 5:50 PM
    After-hours top gainers, as of 5:15 p.m.: OPTR +16%. GTI +9%. DSLV +3%. EGLE +2%. GNMK +2%.
    After-hours top losers: MSPD -8%. CFFN -5%. G -4%. PL -4%. WCRX -2%.
    | Jan. 4, 2013, 5:50 PM
  • Jun. 20, 2012, 1:46 PM

    Medical diagnostic testing systems provider GenMark Diagnostics (GNMK -3.2%) recovers somewhat after dropping over 9% earlier this morning on the announcement of a 10M share secondary offering.

    | Jun. 20, 2012, 1:46 PM
  • Jun. 12, 2012, 12:00 PM

    GenMark Diagnostics (GNMK) +6.6% after it raises its Q2 revenue guidance to $3.2M-$3.6M and says it expects to exceed $15M in the full year vs. a prior prediction of $10M. That's above consensus of $2.4M for Q2 and $12M for the year. (PR)

    | Jun. 12, 2012, 12:00 PM
Company Description
GenMark Diagnostics, Inc. is a molecular diagnostics company which focuses on developing and commercializing its proprietary eSensor detection technology. The company's eSensor XT-8 system is an automated molecular diagnostic system that enables reference laboratories and hospitals to perform... More
Sector: Healthcare
Industry: Medical Appliances & Equipment
Country: United States